OKYO Pharma Ltd ADR
Buy, Hold or Sell?
Let's analyse OKYO Pharma Ltd ADR together
I guess you are interested in OKYO Pharma Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of OKYO Pharma Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
You can find me behind Let's Analyse Together in the top-right of each section.
Get notifications about OKYO Pharma Ltd ADR
I send you an email if I find something interesting about OKYO Pharma Ltd ADR.
Quick analysis of OKYO Pharma Ltd ADR (30 sec.)
1. Valuation of OKYO Pharma Ltd ADR (5 min.)
$1.63
$0.03
2. Growth of OKYO Pharma Ltd ADR (5 min.)
Is OKYO Pharma Ltd ADR growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $560.9k | $1.9m | -$1.6m | -471.9% |
How much money is OKYO Pharma Ltd ADR making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$1m | -$820.4k | -$213.1k | ? |
Net Profit Margin | 0.0% | 0.0% | - | - |
How much money comes from the company's main activities?
3. Financial Health of OKYO Pharma Ltd ADR (5 min.)
4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
Fundamentals of OKYO Pharma Ltd ADR
Financial Health
Compared to previous year | Compared to industry | |
---|---|---|
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry |
---|
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
1.1. Profitability of OKYO Pharma Ltd ADR.
1.1. Profitability
1.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of OKYO Pharma Ltd ADR:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -194.7%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -276.2%. trending up. +2
1.1.2. Return on Assets
- Above 5% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- -126.3% Return on Assets means that OKYO Pharma Ltd ADR generated $-1.26 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is -41.5%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -771.9%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -425.4%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -126.3% | TTM | -111.0% | -15.3% | |
TTM | -111.0% | YOY | -41.5% | -69.4% | |
TTM | -111.0% | 5Y | -771.9% | +660.9% | |
5Y | -771.9% | 10Y | -425.4% | -346.4% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -12.4%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -12.5%. trending down. -2
1.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- -184.3% Return on Equity means OKYO Pharma Ltd ADR generated $-1.84 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is -55.5%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -877.0%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -479.6%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -184.3% | TTM | -138.2% | -46.1% | |
TTM | -138.2% | YOY | -55.5% | -82.7% | |
TTM | -138.2% | 5Y | -877.0% | +738.8% | |
5Y | -877.0% | 10Y | -479.6% | -397.4% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -15.2%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -15.5%. trending down. -2
1.2. Operating Efficiency of OKYO Pharma Ltd ADR.
1.2. Operating Efficiency
1.2.1. Operating Margin
- Measures how much profit OKYO Pharma Ltd ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of OKYO Pharma Ltd ADR:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -319.9%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -274.8%. trending up. +2
1.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of OKYO Pharma Ltd ADR:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.013. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.665. trending down. +2
1.3. Liquidity of OKYO Pharma Ltd ADR.
1.3. Liquidity
1.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 3.17 means the company has $3.17 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is 5.076. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 5.640. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 22.019. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 3.174 | TTM | 2.589 | +0.585 | |
TTM | 2.589 | YOY | 5.076 | -2.487 | |
TTM | 2.589 | 5Y | 5.640 | -3.051 | |
5Y | 5.640 | 10Y | 22.019 | -16.379 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 4.560. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 4.996. trending down. -2
1.3.2. Quick Ratio
- Above 1 is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- A Quick Ratio of 19.76 means the company can pay off $19.76 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is 4.923. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 6.361. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 22.158. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 19.761 | TTM | 6.412 | +13.349 | |
TTM | 6.412 | YOY | 4.923 | +1.488 | |
TTM | 6.412 | 5Y | 6.361 | +0.051 | |
5Y | 6.361 | 10Y | 22.158 | -15.797 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.878. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 4.501. trending up. +2
1.4. Solvency of OKYO Pharma Ltd ADR.
1.3. Liquidity
1.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare OKYO Pharma Ltd ADR to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.31 means that OKYO Pharma Ltd ADR assets are financed with 31.5% credit (debt) and the remaining percentage (100% - 31.5%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is 0.233. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.515. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.264. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.315 | TTM | 0.535 | -0.220 | |
TTM | 0.535 | YOY | 0.233 | +0.301 | |
TTM | 0.535 | 5Y | 0.515 | +0.019 | |
5Y | 0.515 | 10Y | 0.264 | +0.252 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.311. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.298. trending up. -2
1.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- A Debt to Equity ratio of 45.9% means that company has $0.46 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The YOY is 0.315. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.356. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 0.184. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.459 | TTM | 0.344 | +0.115 | |
TTM | 0.344 | YOY | 0.315 | +0.029 | |
TTM | 0.344 | 5Y | 0.356 | -0.012 | |
5Y | 0.356 | 10Y | 0.184 | +0.172 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.363. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.362. trending down. +2
2. Market Valuation of OKYO Pharma Ltd ADR
2. Earnings Per Share
2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
- A PE ratio of -35.38 means the investor is paying $-35.38 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The 5Y is -8.762. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -4.381. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -34.310 | MRQ | -35.384 | +1.074 | |
MRQ | -35.384 | TTM | -43.808 | +8.425 | |
TTM | -43.808 | YOY | - | -43.808 | |
TTM | -43.808 | 5Y | -8.762 | -35.047 | |
5Y | -8.762 | 10Y | -4.381 | -4.381 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -7.202. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -8.445. trending down. +2
2.2. Price Earnings to Growth Ratio
- Lower is better.
- A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.
Let's take a look of the Price Earnings to Growth Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The 5Y is -43.440. Compared to the TTM, the 5Y term is not trending.
- The 10Y is -43.440. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -35.384 | TTM | -43.440 | +8.057 | |
TTM | -43.440 | 5Y | -43.440 | 0.000 | |
5Y | -43.440 | 10Y | -43.440 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Price Earnings to Growth Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -4.294. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -6.108. trending down. +2
2. Book Value per Share
2.3. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 65.20 means the investor is paying $65.20 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of OKYO Pharma Ltd ADR:
Trends
- The 5Y is 1.797. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.899. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 63.221 | MRQ | 65.200 | -1.979 | |
MRQ | 65.200 | TTM | 8.985 | +56.215 | |
TTM | 8.985 | YOY | - | +8.985 | |
TTM | 8.985 | 5Y | 1.797 | +7.188 | |
5Y | 1.797 | 10Y | 0.899 | +0.899 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.024. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.335. trending up. -2
2. Total Gains per Share
3. Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of OKYO Pharma Ltd ADR.
3.1. Institutions holding OKYO Pharma Ltd ADR
Institutions are holding 0.029% of the shares of OKYO Pharma Ltd ADR.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2022-12-31 | UBS Group AG | 0.0346 | 0 | 7523 | 6341 | 536.4636 |
2022-09-30 | Citadel Advisors Llc | 0 | 0 | 0 | -26864 | -100 |
Total | 0.0346 | 0 | 7523 | -20523 | -272.8% |
4. Summary
4.1. Key Performance Indicators
The key performance indicators of OKYO Pharma Ltd ADR compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | - | -0.019 | 0% | -0.018 | 0% | -0.003 | 0% | -0.033 | 0% |
Book Value Growth | - | - | 1.000 | 1.127 | -11% | 1.665 | -40% | 17.490 | -94% | 9.623 | -90% |
Book Value Per Share | - | - | 0.026 | 0.016 | +63% | 0.090 | -71% | 0.048 | -46% | 0.320 | -92% |
Book Value Per Share Growth | - | - | 1.000 | 1.127 | -11% | 1.665 | -40% | 17.490 | -94% | 9.623 | -90% |
Current Ratio | - | - | 3.174 | 2.589 | +23% | 5.076 | -37% | 5.640 | -44% | 22.019 | -86% |
Debt To Asset Ratio | - | - | 0.315 | 0.535 | -41% | 0.233 | +35% | 0.515 | -39% | 0.264 | +19% |
Debt To Equity Ratio | - | - | 0.459 | 0.344 | +33% | 0.315 | +46% | 0.356 | +29% | 0.184 | +149% |
Dividend Per Share | - | - | 0.291 | 0.073 | +300% | - | +100% | 0.015 | +1900% | 0.007 | +3900% |
Eps | - | - | -0.047 | -0.047 | 0% | -0.046 | -4% | -0.216 | +355% | -0.169 | +256% |
Eps Growth | - | - | 1.000 | 1.009 | -1% | - | - | 1.009 | -1% | 1.009 | -1% |
Free Cash Flow Per Share | - | - | -0.048 | -0.048 | 0% | -0.023 | -52% | -0.022 | -53% | -0.032 | -32% |
Free Cash Flow Per Share Growth | - | - | 1.000 | 1.000 | 0% | 0.417 | +140% | 0.863 | +16% | 0.954 | +5% |
Free Cash Flow To Equity Per Share | - | - | -0.048 | -0.048 | 0% | 0.003 | -1471% | -0.015 | -68% | -0.017 | -65% |
Free Cash Flow To Equity Per Share Growth | - | - | 1.000 | 0.516 | +94% | 2.282 | -56% | 1.038 | -4% | 1.013 | -1% |
Gross Profit Margin | - | - | 1.009 | 1.002 | +1% | 1.000 | +1% | 1.000 | +1% | 1.000 | +1% |
Intrinsic Value_10Y_max | - | - | 1.581 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -1.907 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -0.072 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.192 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -0.041 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -0.581 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | 0.202 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -0.968 | - | - | - | - | - | - | - | - |
Net Profit Margin | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Operating Margin | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Operating Ratio | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Pb Ratio | 63.221 | -3% | 65.200 | 8.985 | +626% | - | +100% | 1.797 | +3528% | 0.899 | +7156% |
Pe Ratio | -34.310 | +3% | -35.384 | -43.808 | +24% | - | -100% | -8.762 | -75% | -4.381 | -88% |
Peg Ratio | - | - | -35.384 | -43.440 | +23% | - | - | -43.440 | +23% | -43.440 | +23% |
Price Per Share | 1.629 | -3% | 1.680 | 2.080 | -19% | - | +100% | 0.416 | +304% | 0.208 | +708% |
Price To Total Gains Ratio | 5.595 | -3% | 5.771 | -9.850 | +271% | - | - | -9.850 | +271% | -9.850 | +271% |
Profit Growth | - | - | 1.000 | 1.000 | 0% | 0.905 | +10% | 0.990 | +1% | -4.995 | +600% |
Quick Ratio | - | - | 19.761 | 6.412 | +208% | 4.923 | +301% | 6.361 | +211% | 22.158 | -11% |
Return On Assets | - | - | -1.263 | -1.110 | -12% | -0.415 | -67% | -7.719 | +511% | -4.254 | +237% |
Return On Equity | - | - | -1.843 | -1.382 | -25% | -0.555 | -70% | -8.770 | +376% | -4.796 | +160% |
Total Gains Per Share | - | - | 0.291 | 0.053 | +445% | -0.018 | +106% | 0.011 | +2444% | -0.026 | +109% |
Total Gains Per Share Growth | - | - | 7.280 | 2.612 | +179% | 0.917 | +694% | 4.617 | +58% | 2.764 | +163% |
Usd Book Value | - | - | 560942.180 | 343286.885 | +63% | 1963250.180 | -71% | 1034146.088 | -46% | 6971385.582 | -92% |
Usd Book Value Change Per Share | - | - | - | -0.019 | 0% | -0.018 | 0% | -0.003 | 0% | -0.033 | 0% |
Usd Book Value Per Share | - | - | 0.026 | 0.016 | +63% | 0.090 | -71% | 0.048 | -46% | 0.320 | -92% |
Usd Dividend Per Share | - | - | 0.291 | 0.073 | +300% | - | +100% | 0.015 | +1900% | 0.007 | +3900% |
Usd Eps | - | - | -0.047 | -0.047 | 0% | -0.046 | -4% | -0.216 | +355% | -0.169 | +256% |
Usd Free Cash Flow | - | - | -1040986.100 | -1040986.100 | 0% | -494624.150 | -52% | -489696.213 | -53% | -706320.863 | -32% |
Usd Free Cash Flow Per Share | - | - | -0.048 | -0.048 | 0% | -0.023 | -52% | -0.022 | -53% | -0.032 | -32% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.048 | -0.048 | 0% | 0.003 | -1471% | -0.015 | -68% | -0.017 | -65% |
Usd Price Per Share | 1.629 | -3% | 1.680 | 2.080 | -19% | - | +100% | 0.416 | +304% | 0.208 | +708% |
Usd Profit | - | - | -1033622.910 | -1033622.910 | 0% | -820423.665 | -21% | -4612309.315 | +346% | -3637964.976 | +252% |
Usd Revenue | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Total Gains Per Share | - | - | 0.291 | 0.053 | +445% | -0.018 | +106% | 0.011 | +2444% | -0.026 | +109% |
EOD | +2 -3 | MRQ | TTM | +15 -10 | YOY | +11 -21 | 5Y | +18 -17 | 10Y | +16 -19 |
4.2. Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -34.310 | |
Price to Book Ratio (EOD) | Between | 0-1 | 63.221 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.000 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 19.761 | |
Current Ratio (MRQ) | Greater than | 1 | 3.174 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.315 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.459 | |
Return on Equity (MRQ) | Greater than | 0.15 | -1.843 | |
Return on Assets (MRQ) | Greater than | 0.05 | -1.263 | |
Total | 4/10 (40.0%) |
4.3. Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 53.523 | |
Ma 20 | Greater than | Ma 50 | 1.608 | |
Ma 50 | Greater than | Ma 100 | 1.472 | |
Ma 100 | Greater than | Ma 200 | 1.852 | |
Open | Greater than | Close | 1.550 | |
Total | 2/5 (40.0%) |
Latest Balance Sheet
Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 258 |
Total Stockholder Equity | + 561 |
Total Assets | = 818 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 1 |
Goodwill | 215 |
Intangible Assets | 125 |
Long-term Assets (as reported) | 1 |
---|---|
Long-term Assets (calculated) | 341 |
+/- | 340 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long-term Liabilities (as reported) | 5 |
---|---|
Long-term Liabilities (calculated) | 0 |
+/- | 5 |
Balance Sheet
Currency in USD. All numbers in thousands.
Trend | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 818 | 818 | 1,589 | 818 | 3,274 | 1,285 | 4,177 | 1,285 | 5,138 | 121 | 5,840 | 121 | 483 | 146 | 502 | 146 | 583 | 502 | 1,260 | 502 | 2,008 | 5,562 | 2,876 | 5,562 | 22,246 | 5,599 | 22,388 | 5,599 | 22,395 | 5,748 | 22,669 | 5,748 | 22,992 | 7,091 | 27,759 | 7,091 | 28,363 | 7,437 | 23,428 | 7,437 | 29,748 | 6,589 | 30,594 | 6,589 | 26,357 | 2,503 | 2,503 | 2,503 | 10,013 | 8,980 | 10,001 | 8,980 | 35,920 | 6,678 | 6,678 | 6,678 | 6,678 | 3,478 | 3,478 | 3,478 | 3,478 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 817 | 817 | 1,584 | 817 | 3,270 | 1,266 | 4,113 | 1,266 | 5,062 | 115 | 5,817 | 115 | 458 | 145 | 501 | 145 | 582 | 502 | 1,260 | 502 | 2,008 | 822 | 2,834 | 822 | 3,288 | 934 | 3,628 | 934 | 3,737 | 1,147 | 4,155 | 1,147 | 4,586 | 1,830 | 5,585 | 1,830 | 7,321 | 2,398 | 3,691 | 2,398 | 9,593 | 2,728 | 13,190 | 2,728 | 10,912 | 2,503 | 2,503 | 2,503 | 10,013 | 8,980 | 10,001 | 8,980 | 35,920 | 5,348 | 5,348 | 5,348 | 5,348 | 2,273 | 2,273 | 2,273 | 2,273 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 514 | 514 | 634 | 514 | 2,056 | 1,248 | 3,850 | 1,248 | 4,992 | 47 | 5,762 | 47 | 190 | 120 | 55 | 120 | 481 | 502 | 1,244 | 502 | 2,008 | 786 | 2,667 | 786 | 3,146 | 892 | 3,443 | 892 | 3,569 | 1,091 | 3,942 | 1,091 | 4,366 | 1,776 | 5,348 | 1,776 | 7,104 | 2,359 | 3,511 | 2,359 | 9,437 | 2,660 | 12,938 | 2,660 | 10,640 | 2,500 | 2,500 | 2,500 | 10,001 | 4,419 | 9,990 | 4,419 | 17,677 | 940 | 940 | 940 | 940 | 2,264 | 2,264 | 2,264 | 2,264 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 4,407 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,560 | 0 | 4,560 | 18,238 | 4,407 | 4,407 | 4,407 | 4,407 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 168 | 168 | 484 | 168 | 673 | 14 | 235 | 14 | 55 | 66 | 39 | 66 | 263 | 21 | 422 | 21 | 85 | 0 | 16 | 0 | 0 | 31 | 128 | 31 | 123 | 28 | 124 | 28 | 114 | 40 | 157 | 40 | 160 | 39 | 156 | 39 | 157 | 22 | 94 | 22 | 89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
| 135 | 135 | 466 | 135 | 541 | 4 | 28 | 4 | 15 | 1 | 16 | 1 | 5 | 4 | 0 | 4 | 15 | 0 | 16 | 0 | 0 | 5 | 40 | 5 | 19 | 14 | 60 | 14 | 55 | 15 | 57 | 15 | 61 | 15 | 82 | 15 | 60 | 17 | 87 | 17 | 66 | 68 | 251 | 68 | 272 | 3 | 3 | 3 | 12 | 1 | 11 | 1 | 5 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 1 | 1 | 5 | 1 | 4 | 19 | 64 | 19 | 76 | 6 | 24 | 6 | 25 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 4,740 | 43 | 4,740 | 18,959 | 4,664 | 18,760 | 4,664 | 18,658 | 4,601 | 18,514 | 4,601 | 18,406 | 5,260 | 22,174 | 5,260 | 21,042 | 5,039 | 19,737 | 5,039 | 20,155 | 3,861 | 17,405 | 3,861 | 15,445 | 2,500 | 2,500 | 2,500 | 10,001 | 4,419 | 0 | 4,419 | 17,677 | 1,330 | 1,330 | 1,330 | 1,330 | 1,205 | 1,205 | 1,205 | 1,205 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 1 | 1 | 5 | 1 | 4 | 19 | 64 | 19 | 76 | 6 | 24 | 6 | 25 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3,061 | 43 | 3,061 | 12,245 | 2,986 | 12,046 | 2,986 | 11,944 | 2,923 | 11,800 | 2,923 | 11,692 | 2,936 | 12,874 | 2,936 | 11,742 | 1,875 | 10,437 | 1,875 | 7,499 | 77 | 16,546 | 77 | 307 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 | 1,205 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
| 215 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 107 | 0 | 107 | 429 | 107 | 429 | 107 | 429 | 107 | 429 | 107 | 429 | 161 | 644 | 161 | 644 | 215 | 644 | 215 | 858 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets |
| 125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,571 | 0 | 1,571 | 6,285 | 1,571 | 6,285 | 1,571 | 6,285 | 1,571 | 6,285 | 1,571 | 6,285 | 2,164 | 8,656 | 2,164 | 8,656 | 2,950 | 8,656 | 2,950 | 11,798 | 3,785 | 0 | 3,785 | 15,138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 125 | 125 | 125 | 125 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 258 | 258 | 1,899 | 258 | 1,030 | 321 | 495 | 321 | 1,284 | 149 | 343 | 149 | 596 | 82 | 661 | 82 | 327 | 23 | 167 | 23 | 91 | 52 | 236 | 52 | 207 | 32 | 171 | 32 | 126 | 26 | 146 | 26 | 102 | 37 | 197 | 37 | 149 | 30 | 47 | 30 | 121 | 130 | 300 | 130 | 520 | 12 | 12 | 12 | 49 | 13 | 25 | 13 | 53 | 15 | 15 | 15 | 15 | 18 | 18 | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 258 | 258 | 1,899 | 258 | 1,030 | 309 | 460 | 309 | 1,237 | 144 | 324 | 144 | 575 | 82 | 661 | 82 | 327 | 23 | 167 | 23 | 91 | 52 | 236 | 52 | 207 | 32 | 172 | 32 | 126 | 26 | 146 | 26 | 102 | 37 | 197 | 37 | 149 | 30 | 47 | 30 | 121 | 130 | 300 | 130 | 520 | 12 | 12 | 12 | 49 | 13 | 25 | 13 | 53 | 15 | 15 | 15 | 15 | 18 | 18 | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 25 | 0 | 4 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 141 | 141 | 1,364 | 141 | 565 | 38 | 161 | 38 | 153 | 120 | 258 | 120 | 480 | 73 | 634 | 73 | 293 | 0 | 90 | 0 | 0 | 37 | 218 | 37 | 147 | 22 | 148 | 22 | 86 | 20 | 143 | 20 | 81 | 18 | 177 | 18 | 74 | 12 | 32 | 12 | 48 | 77 | 53 | 77 | 308 | 7 | 7 | 7 | 26 | 13 | 0 | 13 | 53 | 15 | 15 | 15 | 15 | 18 | 18 | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 116 | 116 | 535 | 116 | 465 | 271 | 274 | 271 | 1,059 | 24 | 62 | 24 | 90 | 9 | 27 | 9 | 34 | 23 | 78 | 23 | 91 | 15 | 18 | 15 | 60 | 10 | 24 | 10 | 40 | 5 | 3 | 5 | 21 | 19 | 20 | 19 | 75 | 18 | 15 | 18 | 72 | 53 | 247 | 53 | 212 | 6 | 6 | 6 | 23 | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 5 | 141 | 1,364 | 141 | 565 | 12 | 35 | 12 | 47 | 5 | 19 | 5 | 21 | 73 | 634 | 73 | 293 | 0 | 90 | 0 | 0 | 37 | 218 | 37 | 147 | 22 | -1 | 22 | 86 | 20 | 143 | 20 | 81 | 18 | 177 | 18 | 74 | 12 | 32 | 12 | 48 | 77 | 53 | 77 | 308 | 7 | 7 | 7 | 26 | 13 | 0 | 13 | 53 | 15 | 15 | 15 | 15 | 18 | 18 | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 561 | 561 | -310 | 561 | 2,244 | 964 | 3,682 | 964 | 3,854 | -28 | 5,498 | -28 | -113 | 64 | -159 | 64 | 255 | 479 | 1,092 | 479 | 1,917 | 5,510 | 2,641 | 5,510 | 22,039 | 5,567 | 22,217 | 5,567 | 22,269 | 5,723 | 22,523 | 5,723 | 22,890 | 7,053 | 27,562 | 7,053 | 28,214 | 7,407 | 23,381 | 7,407 | 29,628 | 6,459 | 30,294 | 6,459 | 25,822 | 2,491 | 2,491 | 2,491 | 9,964 | 8,967 | 9,976 | 8,967 | 35,867 | 6,663 | 6,663 | 6,663 | 6,663 | 3,459 | 3,459 | 3,459 | 3,459 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock |
| 23,595 | 23,595 | 78,667 | 23,595 | 94,380 | 0 | 76,371 | 0 | 0 | 16,880 | 67,137 | 16,880 | 67,519 | 17,101 | 68,803 | 17,101 | 68,403 | 16,592 | 66,368 | 16,592 | 66,368 | 16,548 | 66,192 | 16,548 | 66,192 | 16,548 | 0 | 16,548 | 66,192 | 0 | 66,192 | 0 | 0 | 16,488 | 0 | 16,488 | 65,954 | 0 | 59,819 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retained Earnings |
| -21,397 | -21,397 | -81,404 | -21,397 | -85,587 | -18,146 | -74,453 | -18,146 | -72,584 | -17,356 | -70,395 | -17,356 | -69,424 | -17,053 | -69,096 | -17,053 | -68,211 | -16,113 | -65,644 | -16,113 | -64,451 | -11,089 | -63,541 | -11,089 | -44,354 | -11,257 | -45,129 | -11,257 | -45,030 | -11,129 | -44,868 | -11,129 | -44,516 | -9,914 | -39,612 | -9,914 | -39,654 | -7,924 | -38,055 | -7,924 | -31,696 | -4,630 | -30,186 | -4,630 | -18,518 | -1,485 | -1,485 | -1,485 | -5,938 | 4,805 | -5,829 | 4,805 | 19,219 | 2,127 | 2,127 | 2,127 | 2,127 | -375 | -375 | -375 | -375 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 0 | -1,636 | 2,479 | -1,636 | 1,833 | 19,110 | 1,769 | 19,110 | 76,433 | 449 | 8,753 | 449 | 1,790 | 16 | 134 | 16 | 63 | 0 | 369 | 0 | 0 | 112 | -10 | 112 | 69 | 830 | 67,508 | 830 | 1,299 | 16,962 | 1,269 | 16,962 | 67,479 | 548 | 67,139 | 548 | 1,820 | 15,374 | 1,440 | 15,374 | 61,067 | 11,100 | 60,481 | 11,100 | 44,340 | 3,976 | 3,976 | 3,976 | 15,902 | 4,162 | 15,805 | 4,162 | 16,648 | 4,536 | 4,536 | 4,536 | 4,536 | 3,834 | 3,834 | 3,834 | 3,834 |
Balance Sheet
Currency in USD. All numbers in thousands.
Cash Flow
Currency in USD. All numbers in thousands.
Income Statement
Currency in USD. All numbers in thousands.
Latest Income Statement (annual, 2022-03-31)
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 0 | |
Cost of Revenue | -- | |
Gross Profit | - | 0 |
Operating Income (+$) | ||
Gross Profit | - | |
Operating Expense | -4,733 | |
Operating Income | -4,733 | -4,733 |
Operating Expense (+$) | ||
Research Development | 991 | |
Selling General Administrative | - | |
Selling And Marketing Expenses | - | |
Operating Expense | 4,733 | 991 |
Net Interest Income (+$) | ||
Interest Income | 0 | |
Interest Expense | -0 | |
Other Finance Cost | -0 | |
Net Interest Income | 0 | |
Pretax Income (+$) | ||
Operating Income | -4,733 | |
Net Interest Income | 0 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | -4,733 | -4,733 EBIT - interestExpense = -4,733 -4,733 -4,134 |
Interest Expense | 0 | |
Earnings Before Interest and Taxes (EBIT) | -4,733 | -4,733 |
Earnings Before Interest and Taxes (EBITDA) | -4,731 | |
After tax Income (+$) | ||
Income Before Tax | -4,733 | |
Tax Provision | --787 | |
Net Income From Continuing Ops | -5,431 | -3,947 |
Net Income | -4,134 | |
Net Income Applicable To Common Shares | -3,976 | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | 4,733 | |
Total Other Income/Expenses Net | - | 0 |
Technicals of OKYO Pharma Ltd ADR
1. Trend Indicators
1.1 Moving Averages
- Moving averages are lagging trend indicators.
- There are many types of moving averages.
- Moving averages are also used within other indicators.
Directionalities and relatives.
Moving Average | Amount of candles | Trend | Price +/- | vs. MA 50 | vs. MA 100 | vs. MA 200 |
---|---|---|---|---|---|---|
MA 20 | 20 | |||||
MA 50 | 50 | - | ||||
MA 100 | 100 | - | - | |||
MA 200 | 200 | - | - | - |
Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I
1.2 Moving Average Convergence/Divergence (MACD)
- MACD is a lagging momentum indicator.
- Uses two moving averages.
- Can show buy or sell signals based on momentum.
- Can show overbought. and oversold. levels.
Let's take a look of the Moving Average Convergence/Divergence (MACD) of OKYO Pharma Ltd ADR:
- The Moving Average Convergence/Divergence (MACD) is -0.005. The Moving Average Convergence/Divergence (MACD) below zero is a bearish sign. -1
- The MACD is lower than the signal line. This is a bearish indication. -1
1.3 Directional Movement Index (DMI)
The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).
The ADX helps you determine the strength of a trend. Let's take a look of the ADX of OKYO Pharma Ltd ADR:
- The ADX is 31.268. Strong Trend. +1
- The ADX is rising, the current trend is strengthening. +1
- The +DI is higher than the -DI. The current trend is up. +2
1.4 Parabolic SAR
- Parabolic SAR (stop and reverse) is a lagging trend indicator.
- Shows the current trend.
- Shows potential entry signals.
- Shows potential exit signals.
- Can be used to place trailing stoplosses..
2. Momentum Indicators
2.1 Relative Strength Index (RSI)
- Leading momentum indicator, meaning the signals are instant.
- Ranges between 0 and 100.
- Above 70 is considered overbought.
- Below 30 is considered oversold.
- Above or below 50 can also be used to determine price trend or support and resistance.
- RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
- Can be used in many different ways
- The RSI is above 50. +1